Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: A real or magic bullet?

Journal of Controlled Release

Volumn 41, Issue 1-2, 1996, Pages 99-119

  Zelphati, Olivier ^a   Szoka Jr , Francis C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antisense oligonucleotides; Cellular uptake; Drug delivery; Intracellular distribution; Liposomes

Indexed keywords

ANION; ANTISENSE OLIGONUCLEOTIDE; CATION; CHOLESTEROL; DRUG CARRIER; IMMUNOLIPOSOME; LIPOFECTIN; LIPOSOME; NUCLEASE; PHOSPHOROTHIOIC ACID DERIVATIVE; QUATERNARY AMMONIUM DERIVATIVE; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

CELL SPECIFICITY; CELL TYPE; CELLULAR DISTRIBUTION; CONFERENCE PAPER; DRUG POTENCY; DRUG RETENTION; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; GENE EXPRESSION; HUMAN; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PH; PHARMACEUTICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; VIRUS INFECTION;

EID: 0030222163     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(96)01361-2     Document Type: Conference Paper

References (109)

1. [1] E. Uhlmann and A. Peyman, Antisense oligonucleotides: a new therapeutic principle, Chem. Rev. 90 (1990) 544-584.
2. [2] C. Hélène and J.J. Toulmé, Specific regulation of gene expression by antisense, sense and antigen nucleic acids, Biochim. Biophys. Acta 1049 (1990) 99-125.
3. [3] L. Neckers, L. Whitesell, A. Rosolen and D.A. Geselowitz, Antisense inhibition of oncogene expression, Crit. Rev. Oncogen. 3 (1992) 175-231.
4. [4] C.A. Stein and Y.-C. Cheng, Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science 261 (1993) 1004-1012.
5. [5] R.W. Wagner, M.D. Mateucci, J.G. Lewis, A.J. Gutierrez, C. Moulds and B.C. Froehler, Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines, Science 260 (1993) 1510-1513.
6. [6] S.T. Crooke and B. Lebleu, Antisense Research and Applications, CRC Press, Boca Raton, FL, 1993.
7. [7] O. Zelphati, J.-L. Imbach, N. Signoret, G. Zon, B. Rayner and L. Leserman, Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms, Nucleic Acids Res. 22 (1994) 4307-4314.
8. [8] D.D. Lasic, Liposomes from Physics to Applications, Elsevier, Amsterdam, 1993.
9. [9] P. Machy and L. Leserman, Liposomes in Cellular Biology and Pharmacology, John Libbey, 1987.
10. [10] R.M. Bennett, As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells, Antisense Res. Dev. 3 (1993) 235-241.
11. [11] S.L. Loke, C.A. Stein, X.H. Zhang, K. Mori, M. Nakanishi, C. Subasinghe, J.S. Cohen and L.M. Neckers, Characterization of oligonucleotide transport into living cells, Proc. Natl. Acad. Sci. USA 86 (1989) 3474-3478.
12. [12] L.A. Yakubov, E.A. Deeva, V.F. Zarytova, E.M. Ivanova, A.S. Ryte, L.V. Yurchenko and W. Vlassov, Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA 86 (1989) 6454-6458.
13. [13] S.T. Crooke, Therapeutic applications of oligonucleotides, Annu. Rev. Pharmacol. Toxicol. 32 (1992) 329-376.
14. [14] D.A. Geselowitz and L.M. Neckers, Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker, Antisense Res. Dev. 2 (1992) 17-25.
15. [15] G. Goodarzi, M. Watabe and K. Watabe, Binding of oligonucleotides to cell membranes at acidic pH, Biochem. Biophys. Res. Commun. 181 (1991) 1343-1351.
16. [16] I. Kitajima, T. Shinohara, T. Minor, L. Bibbs, J. Bilakovics and M. Nerenberg, Human T-cell Leukemia Virus Type I tax transformation is associated with increased uptake of oligodeoxynucleotides in vitro and in vivo, J. Biol. Chem. 267 (1992) 25881-25888.
17. [17] S. Wu-Pong, T.L. Weiss and C.A. Hunt, Antisense c-myc oligodeoxyribonucleotide cellular uptake, Pharm. Res. 9 (1992) 1010-1017.
18. [18] C.A. Stein, J.L. Tonkinson, L.-M. Zhang, L. Yakubov, J. Gervanosi, R. Taub and S.A. Rotenberg, Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells, Biochemistry 32 (1993) 4855-4861.
19. [19] P. Zamecnik, J. Aghajanian, M. Zamecnik, J. Goodchild and G. Witman, Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes, Proc. Natl. Acad. Sci. USA 91 (1994) 3156-3160.
20. [20] G. Marti, W. Egan, P. Noguchi, G. Zon, M. Matsukura and S. Broder, Oligodeoxyribonucleotide phosphorothioates fluxes and localization in hematopoietic cells, Antisense Res. Dev. 2 (1992) 27-39.
21. [21] S. Akhtar and R.L. Juliano, Cellular uptake and intracellular fate of antisense oligonucleotides, Trends Cell Biol. 2 (1992) 139-145.
22. [22] S. Akhtar, S. Basu, E. Wickstrom and R.L. Juliano, Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes), Nucleic Acids Res. 19 (1991) 5551-5559.
23. [23] Y. Shoji, S. Akhtar, A. Periasamy, B. Herman and R.L. Juliano, Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages, Nucleic Acids Res. 19 (1991) 5543-5550.
24. [24] A.R. Thierry and A. Dritschilo, Intracellular availability of unmodified, phosphorothioted and liposomally encapsulated oligodeoxynucleotides for antisense activity, Nucleic Acids Res. 20 (1992) 5691-5698.
25. [25] D.J. Chin, G.A. Green, G. Zon, F.C.J. Szoka and R.M. Straubinger, Rapid nuclear accumulation of injected oligodeoxyribonucleotides, New Biol. 2 (1990) 1091-1100.
26. [26] Q. Zhao, S. Matson, C.J. Herrera, E. Fisher, H. Yu and A.M. Krieg, Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides, Antisense Res. Dev. 3 (1993) 53-66.
27. [27] J.P. Leonetti, N. Mechti, G. Degols, C. Gagnor and B. Lebleu, Intracellular distribution of microinjected antisense oligonucleotides, Proc. Natl. Acad. Sci. USA 88 (1991) 2702-2706.
28. [28] T.L. Fisher, T. Terhorst, X. Cao and R.W. Wagner, Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells, Nucleic Acids Res. 21 (1993) 3857-3865.
29. [29] S. Sixou, J. Szoka F.C., G.G.A., B. Giusti, G. Zon and D.J. Chin, Intracellular oligonucleotide hybridization detected by fluorescence resonance energy transfer (FRET), Nucleic Acids Res. 22 (1994) 662-668.
30. [30] J.-P. Clarenc, B. Lebleu and J.-P. Leonetti, Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs, J. Biol. Chem. 268 (1993) 5600-5604.
31. [31] M. Lemaitre, B. Bayard and B. Lebleu, Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site, Proc. Natl. Acad. Sci. USA 84 (1987) 648-652.
32. [32] J.P. Leonetti, B. Rayner, M. Lemaitre, C. Gagnor, P.G. Milhaud, J.-L. Imbach and B. Lebleu, Antiviral activity of conjugates between poly(L-lysine) and synthetic oligodeoxyribonucleotides, Gene 72 (1988) 323-332.
33. [33] M. Ceruzzi, K. Draper and J. Schwartz, Natural and phosphorothioate-modified oligodeoxyribonucleotides exhibit a non-random cellular distribution, Nucleosides Nucleotides 9 (1990) 679-695.
34. [34] S.B. Noonberg, M.R. Garovoy and C.A. Hunt, Characteristics of oligonucleotide uptake in human keratinocyte cultures, J. Invest. Derm. 101 (1993) 727-731.
35. [35] W.M. McShan, R.D. Rossen, A.H. Laughter, J. Trial, D.J. Kessler, J.G. Zendegui, M.E. Hogan and F.M. Orson, Inhibition of transcription of HIV-1 in infected human cells by oligodeoxynucleotides designed to form DNA triple helices, J. Biol. Chem. 267 (1992) 5712-5721.
36. [36] R.C. Tam, Y. Li, S. Noonberg, D.G. Hwang, G. Lui, C.A. Hunt and M.C. Garovoy, Biological availability and nuclease resistance extend the in vitro activity of a phosphorothioate-3′hydroxypropylamine oligonucleotide, Nucleic Acids Res. 22 (1994) 977-986.
37. [37] R.M. Crooke, In vitro toxicology and pharmacokinetics of antisense oligonucleotides, Anti-Cancer Drug Design 6 (1991) 609-646.
38. [38] S.L. Loke, C.A. Stein, M. Avigan, J.S. Cohen and L.M. Neckers, Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis, Cur. Top. Microbiol. Immunol. 141 (1988) 282-289.
39. [39] R.M. Burch and L.C. Mahan, Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice, J. Clin. Invest. 88 (1991) 1190-1196.
40. [40] A.R. Thierry, A. Rahmann and A. Dritschilo, Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated oligonucleotides, Biochem. Biophys. Res. Commun. 190 (1993) 952-960.
41. [41] J.J. Rossi, D. Elkins, J.A. Zaia and S. Sullivan, Ribozymes as anti-HIV therapeutic agents: principles, applications, and problems, AIDS Res. Hum. Retroviruses 8 (1992) 183-189.
42. [42] A.M. Tari, S.D. Tucker, A. Deisseroth and G. Lopez-Berestein, Liposomal delivery of methylphosphonate antisense oligo deoxynucleotides in chronic myelogenous leukemia. Blood 84 (1994) 601-607.
43. [43] S. Akhtar and R.L. Juliano, Liposome delivery of antisense oligonucleotides: adsorption and efflux characteristics of phosphorothioate oligodeoxynucleotides, J. Control. Release 22 (1992) 47-56.
44. [44] J.A. Hughes, C.F. Bennett, P.D. Cook, C.J. Guinosso, C.K. Mirabelli and R.L. Juliano, Lipid membrane permeability of 2′-modified derivatives of phosphorothioate oligonucleotides, J. Pharma. Sci. 83 (1994) 597-600.
45. [45] D.C. Litzinger and L. Huang, Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications, Biochim. Biophys. Acta 1113 (1992) 201-227.
46. [46] C.-J. Chu and F.C. Szoka, pH-sensitive liposomes, J. Liposome Res. 4 (1994) 361-395.
47. [47] M. Marsh and A. Helenius, Virus entry into animal cells, Adv. Virus Res. 36 (1989) 107-151.
48. [48] C.-J. Chu, J. Dijkstra, M.-Z. Lai, K. Hong and F.C. Szoka, Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture, Pharm. Res. 7 (1990) 824-834.
49. [49] C. Ropert, M. Lavignon, C. Dubresnet, P. Couvreur and C. Malvy, Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward friend retrovirus, Biochem. Biophys. Res. Commun. 183 (1992) 879-885.
50. [50] C.-Y. Wang and L. Huang, Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes, Biochemistry 28 (1989) 9508-9514.
51. [51] J.-Y. Legendre and F.C. Szoka Jr., Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes, Pharm. Res. 9 (1992) 1235-1242.
52. [52] C. Ropert, C. Malvy and P. Couvreur, Inhibition of the Friend Retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action, Pharm. Res. 10 (1993) 1427-1433.
53. [53] L.D. Leserman, J.N. Weinstein, J.J. Moore and W.D. Terry, Specific interaction of Myeloma tumor cells with hapten-bearing liposomes containing Methotrexate and carboxyfluorescein, Cancer Res. 40 (1980) 4768-4774.
54. [54] T.D. Heath, R.T. Fraley and D. Papahadjopoulos, Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')to vesicle surfaces, Science 210 (1981) 539-541.
55. [55] P. Machy, J. Barbet and L.D. Leserman, Differential endocytosis of T and B lymphocyte surface molecules evaluated with antibody-bearing fluorescent liposomes containing methotrexate, Proc. Natl. Acad. Sci. USA 79 (1982) 4148-4152.
56. [56] P. Machy and L.D. Leserman, Small liposomes are better than large liposomes for specific drug delivery in vitro., Biochim. Biophys. Acta 730 (1983) 313-320.
57. [57] K.K. Matthay, A.M. Abai, S. Cobb, K. Hong, D. Papahadjopoulos and R.M. Straubinger, Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells, Cancer Res. 49 (1989) 4879-4886.
58. [58] H. Suzuki, O. Zelphati, G. Hildebrand and L. Leserman, CD4 and CD7 molecules as targets for drug delivery from antibody bearing liposomes, Exp. Cell Res. 193 (1991) 112-119.
59. [59] J. Barbet, P. Machy, A. Truneh and L. Leserman, Weak acid-induced release of liposome-encapsulated carboxyfluorescein, Biochim. Biophys. Acta 772 (1984) 347-356.
60. [60] T.D. Heath, J.A. Montgomery, J.R. Piper and D. Papahadjopoulos, Antibody-targeted liposomes: increase in specific toxicity of methotrexate-γ-aspartate, Proc. Natl. Acad. Sci. USA 80 (1983) 1377-1381.
61. [61] O. Zelphati, G. Degols, H. Loughrey, L. Leserman, A. Pompon, F. Puech, A.-F. Maggio, J.-L. Imbach and G. Gosselin, Inhibition of HIV-1 replication in cultured cells with phosphorylated dideoxyuridine derivatives encapsulated in immunoliposomes, Antiviral Res. 21 (1993) 181-195.
62. [62] L. Leserman, P. Machy and O. Zelphati, Immunolipo some-mediated delivery of nucleic acids: a review of our aboratory's experience, J. Liposome Res. 4 (1994) 107-119.
63. [63] J.P. Leonetti, P. Machy, G. Degols, B. Lebleu and L. Leserman, Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication, Proc. Natl. Acad. Sci. USA 87 (1990) 2448-2451.
64. [64] O. Zelphati, E. Wagner and L. Leserman, Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes, Antiviral Res. 25 (1994) 13-25.
65. [65] O. Zelphati, G. Zon and L. Leserman, Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes, Antisense Res. Dev. 3 (1993) 323-338.
66. [66] B. Oberhauser and E. Wagner, Effective incorporation of 2′-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol, Nucleic Acids Res. 20 (1992) 533-538.
67. [67] K. Maruyama, S.J. Kennel and L. Huang, Lipid composition is important for highly efficient target binding and retention of immunoliposomes, Proc. Natl. Acad. Sci. USA 87 (1990) 5744-5748.
68. [68] I. Ahmad, M. Longenecker, J. Samuel and T.M. Allen, Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53 (1993) 1484-1488.
69. [69] N.C. Phillips, L. Gagne, C. Tsoukas and J. Dahman, Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status, J. Immunol. 152 (1994) 3168-3174.
70. [70] S.M. Sullivan, R.K.H. Gieseler, S. Lenzner, J. Ruppert, T.G. Gabrysiak, J.H. Peters, G. Cox, L. Richer, W.J. Martin and M.J. Scolaro, Inhibition of human immunodeficiency virus-1 proliferation by liposome-encapsulated sense DNA to the 5′ TAT splice acceptor site, Antisense Res. Dev. 2 (1992) 187-197.
71. [71] F. Szoka, K.E. Magnusson, J. Wojcieszyn, Y. Hou, Z. Derzko and K. Jacobson. Use of lectins and polyethylene glycol for fusion of glycolipid-containing liposomes with eucaryotic cells, Proc. Natl. Acad. Sci. USA 78 (1981) 1685-1689.
72. [72] R. Fraley, S. Subramani, P. Berg and D. Papahadjopoulos, Introduction of liposome-encapsulated SV40 DNA into cells, Proc. Natl. Acad. Sci. USA 255 (1980) 10431-10435.
73. [73] M. Nakanishi and Y. Okada, Liposome-mediated introduction of macromolecules into living animal cells with the aid of HVJ (Sendai virus), in: G. Gregoriadis (Eds.), Liposome Technology: Entrapment of Drugs and Other Materials, Vol. III, CRC Press, Boca Raton, FL, 1993, pp. 249-260.
74. [74] S. Gould-Fogerite and R.J. Mannino, Targeted fusogenic proteoliposomes: functional reconstitution of membrane proteins through protein-cochleate intermediates, in: G. Gregoriadis (Eds.), Liposome Technology: Entrapment of Drugs and Other Materials, III, CRC Press, Boca Raton, FL, 1993, pp. 261-276.
75. [75] J.R. Philippot, P.G. Milhaud, C. Puyal and D.F.H. Wallach, Non-phospholipid molecules and modified phospholipid components of liposomes, in: J.R. Philippot and F. Schuber (Eds.), Liposomes as Tools in Basic Research and Industry, CRC Press, Boca Raton, FL, 1995, pp. 41-57.
76. [76] B. Compagnon, P. Milhaud, A. Bienvenüe and J.R. Philippot, Targeting of Poly(rI)-Poly(rC) by fusogenic (F protein) immuno-liposomes, Exp. Cell Res. 200 (1992) 333-338.
77. [77] R. Morishita, G.H. Gibbons, K.E. Ellison, M. Nakajima, L. Zhang, Y. Kaneda, T. Ogihara and V.J. Dzau, Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia, Proc. Natl. Acad. Sci. USA 90 (1993) 8474-8478.
78. [78] R.T. Earl, I.M. Hunneyball, E.E. Billet and R.J. Mayer, Evaluation of reconstituted Sendai virus envelopes as intraarticular drug vectors: effects on normal and experimentally arthritic rabbit knee joints, J. Pharm. Pharmacol. 40 (1988) 166-170.
79. [79] I. Jääskeläinen, J. Mönkkönen and A. Urtti, Oligonucleotidecationic liposome interactions. A physicochemical study, Biochim. Biophys. Acta 1195 (1994) 115-123.
80. [80] J.P. Behr, Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy, Bioconjugate Chem. 5 (1994) 382-389.
81. [81] S. Capaccioli, G. Di Pasquale, E. Mini, T. Mazzei and A. Quattrone, Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum, Biochem. Biophys. Res. Commun. 197 (1993) 818-825.
82. [82] M.-Y. Chiang, H. Chan, M.A. Zounes, S.M. Freier, W.F. Lima and C.F. Bennett, Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms, J. Biol. Chem. 266 (1991) 18162-18171.
83. [83] C.F. Bennett, M.-Y. Chiang, H. Chan, J.E.E. Shomaker and C.K. Mirabelli, Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides, Mol. Pharmacol. 41 (1992) 1023-1033.
84. [84] K. Lappalainen, A. Urtti, I. Jääskeläinen, K. Syrjänen and S. Syrjänen, Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells, Antiviral Res. 23 (1994) 119-130.
85. [85] H. Itoh, M. Mukoyama, R.E. Pratt and V.J. Dzau, Specific blockade of basic fibroblast growth factor gene expression in endothelial cells by antisense oligonucleotide, Biochem. Biophys. Res. Commun. 188 (1992) 1205-1213.
86. [86] F. Cumin, F. Asselbergs, M. Lartigot and E. Felder, Modulation of human prorenin gene expression by antisense oligonucleotides in transfected CHO cells, Eur. J. Biochem. 212 (1993) 347-354.
87. [87] P.L. Felgner and G.M. Ringold, Cationic liposome-mediated transfection, Nature 337 (1989) 387-388.
88. [88] X. Zhou and L. Huang, DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action, Biochim. Biophys. Acta 1189 (1994) 195-203.
89. [89] O. Zelphati and F.C. Szoka, Intracellular distribution and putative uptake pathway of oligonucleotides delivered by cationic lipids, Manuscript in preparation. (1995).
90. [90] S.M. Stepkowski, Y. Tu, T.P. Condon and C.F. Bennett, Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities, J. Immunol. 153 (1994) 5336-5346.
91. [91] M.E. Miele, C.F. Bennett, B.E. Miller and D.R. Welch, Enhanced metastatic ability of TNF-α-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides, Exp. Cell Res. 214 (1994) 231-241.
92. [92] B.P. Monia, J.S. Johnston, D.J. Ecker, M.A. Zounes, W.F. Lima and S.M. Freier, Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides, J. Biol. Chem. 267 (1992) 19954-19962.
93. [93] L. Perlaky, Y. Saijo, R.K. Busch, C.F. Bennett, C.K. Mirabelli, S.T. Crooke and H. Busch, Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression, Anti-Cancer Drug Design 8 (1993) 3-14.
94. [94] A. Colige, B.P. Sokolov, P. Nugent, R. Baserga and D.J. Prockop, Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells, Biochemistry 32 (1993) 7-11.
95. [95] T. Vickers, B.F. Baker, P.D. Cook, M. Zounes, R.J. Buckheit, J. Germany and D.J. Ecker, Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element, Nucleic Acids Res. 19 (1991) 3359-68.
96. [96] M. Sioud, J.B. Natvig and Ø. Førre, Preformed ribozyme destroys tumour necrosis factor mRNA in human cells, J. Mol. Biol. 223 (1992) 831-835.
97. [97] P. Pinnaduwage, L. Schmitt and L. Huang, Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells, Biochim. Biophys. Acta 985 (1989) 33-37.
98. [98] Y.A. Hannun and R.M. Bell, Functions of sphingolipids and sphingolipid breakdown products in cellular regulation, Science 243 (1989) 500-507.
99. [99] R. Leventis and J.R. Silvius, Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles, Biochim. Biophys. Acta 1023 (1990) 124-132.
100. [100] J.H. Senior, K.R. Trimble and R. Maskiewicz, Interaction of positively-charged liposomes with blood: implications for their application in vivo, Biochim. Biophys. Acta 1070 (1991) 173-179.
101. [101] P.L. Felgner and G. Rhodes, Gene therapeutics, Nature 349 (1991) 351-2.
102. [102] N. Dean and R. McKay, Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides, Proc. Natl. Acad. Sci. USA 91 (1994) 11762-11766.
103. [103] S. Agrawal, J. Temsamani and J.Y. Tang, Pharmacokinetics, biodistribution, and stability os oligodeoxynucleotide phosphorothioates in mice, Proc. Natl. Acad. Sci. USA 88 (1991) 7595-7599.
104. [104] P. Iversen, In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue, Anti-Cancer Drug Design 6 (1991) 531-538.
105. 14C-labelled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats, J. Pharmacol. Exp. Ther. 269 (1994) 89-94.
106. [106] J. Goodchild, B. Kim and P.C. Zamecnik, The clearance and degradation of oligodeoxynucleotides following intravenous injection into rabbits, Antisense Res. Dev. 1 (1991) 153-160.
107. [107] G. Goodarzi, M. Watabe and K. Watabe, Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice, Biopharm. Drug Disposition 13 (1992) 221-227.
108. [108] P. Iversen, In vivo studies with phosphorothioate oligonucleotides: rationale for systemic therapy, in: S.T. Crooke and B. Lebleu (Eds.), Antisense Research and Applications, CRC Press, Boca Raton, FL, 1993, Ch. 26.
109. [109] D.D. Lasic and D. Papahadjopoulos, Liposomes revisited, Science 267 (1995) 1275-1276.